Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | CCR5 | P51681 | 3/20 | 0.45 |
| ▸ | CCR8 | P51685 | 3/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.44 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401093 | 0.77 | CYP2A6 (0.34) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| SCHEMBL4397412 | 0.77 | CYP1A2 (0.34) | CYP1A2CYP2A6 | |
| SCHEMBL4402445 | 0.77 | CYP2A6 (0.34) | CYP1A2CYP2A6KMT2A | |
| SCHEMBL16223776 | 0.77 | ALDH1A1 (0.36) | KDM4EALDH1A1TDP1 | |
| SCHEMBL10321126 | 0.77 | CYP1A2 (0.41) | CYP1A2ALDH1A1CYP2A6PDK2 | |
| SCHEMBL3824244 | 0.74 | KDM4E (0.47) | KDM4EPARP1ALDH1A1CYP2A6TDP1 | |
| SCHEMBL4399735 | 0.72 | PDGFRB (0.56) | CYP1A2KDM4EALDH1A1CYP2A6KMT2A | |
| SCHEMBL7976174 | 0.71 | CYP1A2 (0.36) | CYP1A2CYP2A6 | |
| SCHEMBL7972525 | 0.69 | CYP1A2 (0.41) | CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL5071855 | 0.69 | CYP1A2 (0.50) | CYP1A2CCR1CCR5CCR8PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | claimed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | claimed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | claimed |
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | claimed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| EP-0565396-B1 | 1-[2-(arylsulfonylamino)-1-oxoethyl]piperidine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1998-01-07 | — | — | EP | claimed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | claimed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | claimed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | claimed |
| US-5453430-A | Anticoagulants | SYNTHELABO (FR) | 1995-09-26 | — | — | US | claimed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | claimed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | CYP1A2 299/4885CCR1 4779/4885CCR5 3353/4885 |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | CYP1A2 2867/4885CCR1 1901/4885CCR5 1645/4885 |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | OXTR, AVPR2, AVPR1A | CYP1A2 227/4885CCR1 1890/4885CCR5 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.